Key trends to watch

The growing
market in
Mainland China

We identified nine drugs that are likely to achieve the traditional $1 billion
blockbuster status in Mainland China by 2030, including both global and
domestically manufactured assets

Download the report

Including a Mainland China approach within the market plan can extend the revenue-generating life of these drugs beyond the expected patent expiry in the United States and Europe.

Of the nine selected, eight are oncology drugs, which is likely driven by healthcare reforms under Healthy China 2030 that have placed a focus on addressing the increasing cancer burden in Mainland China. It was estimated that 4.8 million new cancer cases and 3.2 million cancer-related deaths would occur in Mainland China in 2022.

Game-changers in
Mainland China

Drug Company(s) U.S. approval European Approval Mainland China approval 2021 Sales in Mainland China ($M) Expected patent expiry in Mainland China
Anlotinib (Focus V®) Chia Tai Tianqing Pharmaceutical (CTTQ) N/A N/A 2018 620 2028
Atezolizumab (TECENTRIQ®) Genentech 2016 2017 2020 3,300 2029
Camrelizumab (AiRuiKa™) Jiangsu Hengrui Medicine Co Ltd N/A N/A 2019 600 2036
Nivolumab (OPDIVO®) Bristol Myers Squibb 2014 2015 2018 7,523 2026
Pembrolizumab (KEYTRUDA®) Merck 2014 2016 2018 17,200 2028
Sacubitril/valsartan (ENTRESTO®) Novartis 2015 2015 2017 3,548 2027
Sintilimab (TYVYT®) Innovent Biologics Inc and Eli Lilly and Company N/A 2020 2018 418 2036
Tislelizumab (Baize'an) BeiGene N/A N/A 2019 255 2033
Trastuzumab (HERCEPTIN®) Roche 1998 2000 2002 2,700 Biosimilars available

Sources: BioWorld, Novartis Annual Report 2021, Eli Lilly and Company Annual Report 2021, BeiGene Annual Report 2021, Roche Annual Report 2021, Bristol Myers Squibb press release, Merck press release,

From innovation to bottom line

Access global intelligence, advanced analytics and global experts from Clarivate.

Contact our team